Arthritis News and Research

Latest Arthritis News and Research

New silicon chips help identify patients with lupus

Researchers at the Stanford University School of Medicine and Intel Corp. have collaborated to synthesize and study a grid-like array of short pieces of a disease-associated protein on silicon chips normally used in computer microprocessors.

21 Aug 2012

Kineta receives regulatory clearance to commence ShK-186 Phase I trial in autoimmune disease

Seattle-based biotech company Kineta, Inc. announced today it has received regulatory clearance in the Netherlands to initiate a first-in-human trial of ShK-186, an autoimmune drug candidate that specifically inhibits the Kv1.3 potassium ion channel.

21 Aug 2012

Medivir initiates MIV-711 phase Ib trial in healthy volunteers

Medivir AB, the research-based pharmaceutical company focused on the development of high-value treatments for infectious diseases, is reporting today that a clinical phase Ib trial of the company's candidate drug (CD) MIV-711 has commenced.

21 Aug 2012

New attack on arthritis pain

A research team from the University of Melbourne is working on a new therapy that can potentially control the pain caused by diseases such as rheumatoid arthritis and osteoarthritis.

21 Aug 2012

Arthritis patients prioritize lifestyle intervention research

Most patients believe that research into joint pain should focus on self-management and lifestyle modifications, suggests a UK survey of older individuals with self-reported joint pain.

20 Aug 2012

Happtique introduces mRx solution for electronically prescribing medical apps

Happtique, a mobile health application store and total app management solution, today announced the commencement of its pilot program of mRx, Happtique's patent-pending solution that enables physicians and other health practitioners to electronically prescribe medical, health, and fitness apps to their patients.

20 Aug 2012

'Yoga for Healthy Lower Backs' likely to be cost effective for both NHS and wider society

Specialised group yoga classes could provide a cost-effective way of treating patients with chronic or recurrent low back pain, according to the UK's largest ever study of the benefits of yoga.

17 Aug 2012

Preliminary results from Lexicon’s Phase 1 studies of LX2931 and LX7101 for RA

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering breakthrough treatments for human disease, today reported preliminary results from Phase 1 studies of LX2931 and LX7101.

17 Aug 2012

Tofacitinib shows promise in active ulcerative colitis

Tofacitinib can induce a clinical response in the majority of patients with moderate to severe, active ulcerative colitis, a placebo-controlled trial has shown.

16 Aug 2012

Tofacitinib drug shows promise against moderate-to-severe ulcerative colitis

An investigational drug currently under FDA review for the treatment of rheumatoid arthritis has now shown positive results in patients with moderate-to-severe ulcerative colitis, according to researchers at the University of California San Diego, School of Medicine.

16 Aug 2012

APS’ Sharon S. Keller Chronic Pain Research Program to award $150,000 for eligible members

The American Pain Society (APS) announced today it is accepting applications for research grants from the newly established Sharon S. Keller Chronic Pain Research Program.

16 Aug 2012

CD4 T cells orchestrate inflammatory attack on the artery wall

Most people probably know that heart disease remains the nation's No. 1 killer. But what many may be surprised to learn is that cholesterol has a major accomplice in causing dangerous arterial plaque buildup that can trigger a heart attack. The culprit? Inflammatory cells produced by the immune system.

15 Aug 2012

Cathepsins may attack one another instead of the bodily proteins

Researchers for the first time have shown that members of a family of enzymes known as cathepsins - which are implicated in many disease processes - may attack one another instead of the bodily proteins they normally degrade. Dubbed "cathepsin cannibalism," the phenomenon may help explain problems with drugs that have been developed to inhibit the effects of these powerful proteases.

15 Aug 2012

New class of drugs may prove useful in treating cancer and aging-associated disorders

In a study published in the Proceedings of the National Academy of Sciences (PNAS) on Aug. 6, an international team led by Igor Roninson, of the University of South Carolina and the Medical University of South Carolina, reported the development of a new class of drugs that may prove useful in the treatment of cancer and aging-associated disorders.

14 Aug 2012

Tofacitinib efficacy suggested for rheumatoid arthritis

The novel oral Janus kinase inhibitor tofacitinib significantly reduces signs and symptoms of rheumatoid arthritis, report two phase III trials published in TheNew England Journal of Medicine.

13 Aug 2012

Twelve states currently have adult obesity rate above 30%

Twelve states currently have an adult obesity rate above 30 percent, according to a new analysis released today by the Trust for America's Health (TFAH) and the Robert Wood Johnson Foundation (RWJF).

13 Aug 2012

Promising stem cell therapy may prevent osteoarthritis after joint injury

Duke researchers may have found a promising stem cell therapy for preventing osteoarthritis after a joint injury.

10 Aug 2012

Longer looks: Waking up to the need for sleep

Among the more than 11,000 dearly departed inhabitants of Southeast Portland's Multnomah Park Cemetery, friends Eric Cordingley and David Anderson have their favorites: a reputed French madam, a young Norwegian institutionalized for being gay, and Louis Napoleon Lepley -- or, as they call him, "Louis the cannibal." Intriguing as their individual stories may be, together they help tell a bigger, darker tale

10 Aug 2012

Internet poor for foot and ankle patients

Foot and ankle patients seeking education on the internet are likely to come across poor quality information on their diagnosis, US researchers warn.

9 Aug 2012

Amgen announces decision to stop ganitumab Phase 3 trial in advanced pancreatic cancer

Amgen today announced a decision to stop the ganitumab (AMG 479) Phase 3 GAMMA (Gemcitabine and AMG 479 in Metastatic Adenocarcinoma of the Pancreas) trial following the recommendation of an independent Data Monitoring Committee (DMC) overseeing the trial.

9 Aug 2012